PF 04217903 mesylate

Key Product Details

Product Description

PF 04217903 mesylate is a highly selective, high affinity MET inhibitor (K_i = 6-7 nM against wild type c-Met). Displays >1000-fold selectivity for c-Met over a panel of 208 kinases.

Licensing Information

Sold for research purposes under agreement from Pfizer Inc.

Product Specifications for PF 04217903 mesylate

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for PF 04217903 mesylate

The following data is based on the product molecular weight 468.49.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

2 1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	2.13 mL	10.67 mL	21.35 mL
5 mM	0.43 mL	2.13 mL	4.27 mL
10 mM	0.21 mL	1.07 mL	2.13 mL
50 mM	0.04 mL	0.21 mL	0.43 mL

Calculators

Background References

References are publications that support the biological activity of the product. See our Citations tab to view 5 publications citing the usage of this product.

• Cui Discovery of a novel class of exquisitely selective mesenchymal-epithelial transition factor (c-MET) protein kinase inhibitors and identification of the clinical candidate 2-(4-(1-(quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6- J.Med.Chem. 2012 PMID: 22924734
• Timofeevski Enzymatic characterization of c-Met receptor tyrosine kinase oncogenic mutants and kinetic studies with aminopyridine and triazolopyrazine inhibitors. Biochemistry 2009 PMID: 19459657
• Underiner Discovery of small molecule c-Met inhibitors: evolution and profiles of clinical candidates. Anticancer Agents Med.Chem. 2010 PMID: 20015007
• Eder Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin.Cancer Res. 2009 PMID: 19318488

Product Documents for PF 04217903 mesylate